HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Pathogens · 2025
DOI: 10.3390/pathogens14010048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Nalia Ismael und 14 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Saúde, Estrada Nacional N1, Marracuene 3943, Mozambique. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, HIV Infections, Oxazines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centres for Disease Control and Prevention (CDC), U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).
Abstract (Originalsprache)
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months who transitioned to TLD and had unsuppressed viral load (VL) ≥ 1000 copies/mL six months post-transition. After three adherence counseling sessions, participants with VF underwent genotyping for drug resistance mutations (DRMs) using the Stanford HIVdb Program. Of 717 participants (median age 39.2 years, 70.7% female), 217 (30.2%) had VF, 193 (88.9%) underwent genotyping, with 183 (94.8%) successfully genotyped. Intermediate–high dolutegravir (DTG) resistance was found in 19.6% (36/183). Unsuppressed VL before DTG transition was independently associated with VF (aOR: 2.14). Resistance patterns included 33.3% (12/36; 95% CI: 14.6–46.3) to all three TLD drugs, 55.6% (20/36; 95% CI: 39.3–71.9) to DTG and 3TC, and 11% (4/36; 95% CI: 0.8–21.3) to DTG only. Major drug resistance mutations to DTG included G118R (9.3%), R263K (6.6%), and Q148H/R/K (4.4%). This study highlights the need to consider virologic status before transitioning PLHIV to TLD and suggests that adherence counseling may not prevent resistance in those with unknown or prior VF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Nacional de Saúde, Estrada Nacional N1, Marracuene 3943, Mozambique.
- Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 8000, South Africa.
- Elizabeth Glaser Pediatric AIDS Foundation, Avenida Paulo Samuel KanKhomba, 280 Bairro da Sommerschield, Maputo 20005, Mozambique.
- National HIV and STI Control Program, Ministry of Health, Salvador Allende 1008, Maputo 1101, Mozambique.
- Operational Research Unit, Gaza Provincial Health Directorate, Rua do Hospital Provincial, 33 Bairro 13, Cidade de Xai-Xai 1200, Mozambique.
- Division of Global HIV & TB, U.S. Centers for Diseases Control and Prevention, Avenida Marginal 5467, Maputo 1101, Mozambique.
ORCID-Profile: Nalia Ismael, Cacildo Magul, Mahoudo Bonou, Artur Ramos, Lauren Greenberg
Förderung
- U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centres for Disease Control and Prevention (CDC)
- U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)
Zitieren
APA
Ismael, N., Hussein, C., Magul, C., Inguane, H., Couto, A., Nhangave, A., Muteerwa, A., Bonou, M., Ramos, A., Young, P. W., Chilundo, S., Machekano, R., Greenberg, L., da Silva, J., & Bhatt, N. (2025). HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique. Pathogens. https://doi.org/10.3390/pathogens14010048
Vancouver
Ismael N, Hussein C, Magul C, Inguane H, Couto A, Nhangave A, et al. HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique. Pathogens. 2025. doi:10.3390/pathogens14010048
BibTeX
@article{Ismael2025,
author = {Ismael, Nalia and Hussein, Cidia and Magul, Cacildo and Inguane, Humberto and Couto, Aleny and Nhangave, Amancio and Muteerwa, Ana and Bonou, Mahoudo and Ramos, Artur and Young, Peter Wesley and Chilundo, Sonia and Machekano, Rhoderick and Greenberg, Lauren and da Silva, Juliana and Bhatt, Nilesh},
title = {HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14010048}
}
EUVIMED